TP53 and neoplasm: Hence, based upon this data, an Ad-p53 dose of 1 x 1011 vp/cm3 of tumor volume was chosen for a new trial combining Ad-p53 with anti-PD-1 therapy NCT03544723 (https://clinicaltrials.gov/ct2/show/NCT03544723.